Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.03. | NANOLLOSE LIMITED: NC6 Selected for Fashion For Goods 2024 Innovation Programme | - | ASX | ||
23.02. | NANOLLOSE LIMITED: Half Yearly Report and Accounts | 2 | ASX | ||
20.02. | NANOLLOSE LIMITED: Australian Patent Approval Granted for JelliGrow Technology | 1 | ASX | ||
12.02. | Australia's Nanollose hits near 3-month high on order win | 1 | Reuters | ||
11.02. | NANOLLOSE LIMITED: Maiden Purchase Order Secured From Global Denim Manufacturer | - | ASX | ||
07.02. | NANOLLOSE LIMITED: NC6OB Distribution Schedule | - | ASX | ||
07.02. | NANOLLOSE LIMITED: NC6OB Top 20 Holders | - | ASX | ||
06.02. | NANOLLOSE LIMITED: Change of Director's Interest Notice x 2 | - | ASX | ||
06.02. | NANOLLOSE LIMITED: Appendix 2A | - | ASX | ||
06.02. | NANOLLOSE LIMITED: Completion of Share Purchase Plan | - | ASX | ||
06.02. | NANOLLOSE LIMITED: Application for quotation of securities - NC6 | - | ASX | ||
29.01. | NANOLLOSE LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
25.01. | NANOLLOSE LIMITED: Results of Meeting | 1 | ASX | ||
18.12.23 | NANOLLOSE LIMITED: Security Purchase Plan - Prospectus | 1 | ASX | ||
18.12.23 | NANOLLOSE LIMITED: Notice of General Meeting/Proxy Form | 1 | ASX | ||
06.12.23 | NANOLLOSE LIMITED: Change of Director's Interest Notice | - | ASX | ||
06.12.23 | NANOLLOSE LIMITED: Notification regarding unquoted securities - NC6 | - | ASX | ||
05.12.23 | NANOLLOSE LIMITED: Third Pilot Spin Completed With Birla Cellulose | - | ASX | ||
30.11.23 | NANOLLOSE LIMITED: Resignation of Company Secretary | - | ASX | ||
24.11.23 | NANOLLOSE LIMITED: Meeting Results | - | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PAION | 0,040 | +17,75 % | Schock-News für Paion Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
NANOREPRO | 1,730 | +1,17 % | EQS-News: NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen | EQS-News: NanoRepro AG
/ Schlagwort(e): Aktienrückkauf
NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen
15.04.2024 / 09:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
4SC | 8,220 | -3,07 % | PTA-News: 4SC AG: Freistellung vom pädiatrischen Untersuchungsplan (PIP) für Resminostat von der britischen MHRA erhalten | DJ PTA-News: 4SC AG: Freistellung vom pädiatrischen Untersuchungsplan (PIP) für Resminostat von der britischen MHRA erhalten
Unternehmensmitteilung für den Kapitalmarkt
Planegg-Martinsried... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 1,738 | 0,00 % | Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive | WASHINGTON (dpa-AFX) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) Monday said it presented positive topline results from the Phase 3 MELODY-1 study of its drug candidate PL9643... ► Artikel lesen | |
BRAIN BIOTECH | 2,970 | +3,12 % | EQS-News: BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Sonstiges
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
16.04.2024 / 11:20 CET/CEST
Für... ► Artikel lesen | |
BIOXXMED | 0,550 | +1,85 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Shelly Group, Valneva | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
AAP IMPLANTATE | 0,800 | +5,26 % | EQS-Adhoc: aap Implantate AG: aap Verschiebung der Veröffentlichung des Konzernabschlusses 2023 aufgrund personeller Engpässe | EQS-Ad-hoc: aap Implantate AG / Schlagwort(e): Jahresbericht
aap Implantate AG: aap Verschiebung der Veröffentlichung des Konzernabschlusses 2023 aufgrund personeller Engpässe
17.04.2024... ► Artikel lesen | |
CLINUVEL | 8,830 | -0,06 % | CLINUVEL PHARMACEUTICALS LIMITED: Change to executive management | ||
SANGAMO THERAPEUTICS | 0,494 | +2,92 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
SCORPIUS | 0,152 | +2,01 % | Scorpius Holdings, Inc.: Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 | Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023 Achieves Record Backlog of $9.3 Million... ► Artikel lesen | |
AETERNA ZENTARIS | 1,820 | -1,09 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
BIO-GATE | 1,030 | 0,00 % | BioGate Precision Medicine Corp.: A Global Milestone in Innovative Pancreatic Cancer Therapy | Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy... ► Artikel lesen | |
EDITAS MEDICINE | 4,992 | -3,22 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates | Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates... ► Artikel lesen | |
TREVENA | 0,360 | +8,43 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
EVOLVA | 1,005 | +1,98 % | Adhoc: Evolva Holding SA: Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected | Evolva Holding SA / Key word(s): AGMEGM
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction... ► Artikel lesen |